Upon joining the study, the patient will be randomly assigned to one of two groups: one receiving the combination therapy of avutometinib and defactinib, and the other receiving a treatment chosen by the investigator from a list of approved options.

If assigned to the combination therapy group, the patient will take avutometinib and defactinib orally. The specific dosage and frequency will be determined by the study protocol.

If assigned to the investigator’s choice group, the patient may receive one of the following treatments: pegylated liposomal doxorubicin (infusion), paclitaxel (infusion), topotecan (infusion), letrozole (oral tablet), or anastrozole (oral tablet). The dosage and frequency will depend on the specific medication and the patient’s medical history.

Throughout the trial, the patient’s health and response to treatment will be closely monitored. This includes regular visits for physical examinations, blood tests, and imaging studies to assess the progression of the disease.

The primary goal is to evaluate progression-free survival, which means the length of time during and after treatment that the patient lives with the disease without it getting worse.

The treatment will continue until the disease progresses, unacceptable side effects occur, or the patient decides to withdraw from the study.

After the treatment ends, follow-up visits may be scheduled to monitor the patient’s health and gather additional data on overall survival and other outcomes.